BioDelivery Sciences Appoints Terry Coelho as Chief Financial Officer
15 janv. 2019 07h30 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Jan. 15, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences to Host Institutional Investor and Analyst Day on Friday, October 5, 2018
13 sept. 2018 07h30 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 13, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Reports Strong Second Quarter 2018 Financial Results
09 août 2018 16h05 HE
|
BioDelivery Sciences International, Inc.
BELBUCA® Continues Its Accelerated Record Prescription Growth of 80% YOY and 31% Versus the Prior Quarter Company Provides Overview of New Plan to Capitalize on Long Term Net Revenue Potential of...
Sucampo Pharmaceuticals Announces its Participation at the Global Mizuho Investor Conference
27 nov. 2017 16h10 HE
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will participate in investor...
Sucampo to Host 2017 R&D Day on November 16 in New York
09 nov. 2017 17h48 HE
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its 2017 R&D Day...
Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation
28 sept. 2017 17h34 HE
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that the U.S. Food and Drug...
Sucampo Reports Second Quarter 2017 Financial Results
02 août 2017 06h30 HE
|
Sucampo Pharmaceuticals Inc
Patent Issued for Pipeline Compound VTS-270 for Niemann-Pick Disease Type C1 Diluted EPS Loss of $3.92 Resulting from $186.6M IP R&D Second Quarter Charge Due to Accounting Treatment of Vtesse...
Sucampo Acquires Vtesse Inc.
03 avr. 2017 06h30 HE
|
Sucampo Pharmaceuticals Inc
Transaction Valued at $200 Million Upfront Diversifies Pipeline with Late Stage Program in Niemann-Pick Disease Type C1 (NPC-1) Increases Company Focus on Specialized Diseases with High Unmet Need ...
Sucampo Reports Fourth Quarter and Full Year 2016 Financial Results
08 mars 2017 06h30 HE
|
Sucampo Pharmaceuticals Inc
Continued Revenue Growth Leads to Strong Income Growth Company Reiterates 2017 Guidance Company Announces Key Executive Transitions Company to Host Conference Call Today at 8:30 a.m. EST ...
Sucampo Announces Fourth Quarter and Full Year 2016 Earnings Call
23 févr. 2017 16h02 HE
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its fourth quarter and...